Twist Bioscience Rallies as Anthropic Adds AI Validation, but Operating Proof Still Pending

What happened

Twist Bioscience shares rose after Anthropic selected the company as an independent evaluator in a new AI-driven protein design campaign, adding a fresh AI-related catalyst to an already crowded narrative. The news follows the earlier Amazon Bio Discovery partnership and comes despite a recent Scorpion Capital short report, showing that AI-hype momentum is outweighing fundamental concerns in the near term. While the Anthropic designation likely reinforces Twist's positioning in AI-enabled biologics, it provides no disclosed revenue or bookings, similar to the Amazon agreement that has yet to show quantifiable conversion. The latest master report rated TWST a WAIT with conviction 4.0, citing that the stock at $101 already prices in AI monetization and breakeven, while operating losses and cash burn continue. The next quarterly filing remains critical: it must show FY26 Q4 adjusted EBITDA breakeven, gross margin above 52%, and first quantified evidence of AI-linked demand to justify the current valuation.

Implication

Investors should treat the Anthropic news as incremental narrative support rather than a fundamental change. The stock's resilience after a short report and surge on an unquantified AI partnership suggest the market may be over-extrapolating AI tailwinds. The core concerns remain: Q3 FY26 adjusted EBITDA was negative $11.3M, nine-month operating loss was $115M, and cash burn increased. Management's own breakeven target is Q4, so the next earnings release is a make-or-break event. If the company misses breakeven or fails to show Amazon/Anthropic conversion, the stock is vulnerable to a sharp de-rating. Conversely, a beat on all three metrics could push the stock toward the bull-case $125. For now, the appropriate stance is to wait for proof rather than chase momentum.

Thesis delta

The thesis remains unchanged: Twist has a real but unproven AI monetization story. The Anthropic news adds another high-profile partner but still no revenue or bookings. The WAIT rating stands; the next filing must convert narrative into financial evidence before a shift to BUY is warranted.